"Azepines" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Seven membered heterocyclic rings containing a NITROGEN atom.
| Descriptor ID |
D001381
|
| MeSH Number(s) |
D03.383.066
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Azepines".
Below are MeSH descriptors whose meaning is more specific than "Azepines".
This graph shows the total number of publications written about "Azepines" by people in this website by year, and whether "Azepines" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2007 | 0 | 1 | 1 |
| 2008 | 3 | 0 | 3 |
| 2009 | 1 | 0 | 1 |
| 2010 | 3 | 0 | 3 |
| 2011 | 0 | 2 | 2 |
| 2012 | 0 | 1 | 1 |
| 2016 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Azepines" by people in Profiles.
-
Hyman DM, Sill MW, Lankes HA, Piekarz R, Shahin MS, Ridgway MR, Backes F, Tenney ME, Mathews CA, Hoffman JS, Aghajanian C, Hensley ML. A phase 2 study of alisertib (MLN8237) in recurrent or persistent uterine leiomyosarcoma: An NRG Oncology/Gynecologic Oncology Group study 0231D. Gynecol Oncol. 2017 Jan; 144(1):96-100.
-
Lehman NL, O'Donnell JP, Whiteley LJ, Stapp RT, Lehman TD, Roszka KM, Schultz LR, Williams CJ, Mikkelsen T, Brown SL, Ecsedy JA, Poisson LM. Aurora A is differentially expressed in gliomas, is associated with patient survival in glioblastoma and is a potential chemotherapeutic target in gliomas. Cell Cycle. 2012 Feb 1; 11(3):489-502.
-
Marmura MJ, Silberstein SD. Current understanding and treatment of headache disorders: five new things. Neurology. 2011 Feb 15; 76(7 Suppl 2):S31-6.
-
Butler TM, Siegman MJ. A force-activated kinase in a catch smooth muscle. J Muscle Res Cell Motil. 2011 Mar; 31(5-6):349-58.
-
Ho TW, Olesen J, Dodick DW, Kost J, Lines C, Ferrari MD. Antimigraine efficacy of telcagepant based on patient's historical triptan response. Headache. 2011 Jan; 51(1):64-72.
-
Dodick DW, Kost J, Assaid C, Lines C, Ho TW. Sustained pain freedom and no adverse events as an endpoint in clinical trials of acute migraine treatments: application to patient-level data from a trial of the CGRP receptor antagonist, telcagepant, and zolmitriptan. Cephalalgia. 2011 Feb; 31(3):296-300.
-
Ho AP, Dahlöf CG, Silberstein SD, Saper JR, Ashina M, Kost JT, Froman S, Leibensperger H, Lines CR, Ho TW. Randomized, controlled trial of telcagepant over four migraine attacks. Cephalalgia. 2010 Dec; 30(12):1443-57.
-
Tepper SJ, Cleves C. Telcagepant, a calcitonin gene-related peptide antagonist for the treatment of migraine. Curr Opin Investig Drugs. 2009 Jul; 10(7):711-20.
-
Ho TW, Ferrari MD, Dodick DW, Galet V, Kost J, Fan X, Leibensperger H, Froman S, Assaid C, Lines C, Koppen H, Winner PK. Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial. Lancet. 2008 Dec 20; 372(9656):2115-23.
-
Kumar SK, Mather PJ. AVP receptor antagonists in patients with CHF. Heart Fail Rev. 2009 Jun; 14(2):83-6.